ISLHD CARDIOVASCULAR CLINICAL TRIALS

Illawarra Heart Health Centre February 2025

ISLHD CARDIOVASCULAR CLINICAL TRIALS UNIT

> Illawarra Heart Health Centre

Wollongong Hospital Loftus Street Wollongong NSW 2500

> Ph 02 4253 4908 Fax 02 4253 4950

Team

A/Prof Astin Lee Director of Cardiology Stephen Mackay Trial Lead Martin Walker Trial Coordinator Shaunagh Napier Research Officer The Illawarra Shoalhaven Local Health District (ISLHD) Cardiovascular Clinical Trials Unit is situated at the Illawarra Heart Health Centre in Wollongong Hospital. It boasts a specialised team comprising doctors, nurses, and allied health professionals.

This unit actively supports a range of clinical trials, contributing to evidence-based practices, fostering knowledge development and enhancing patient care within the local community.



Welcome 2025!

After a well-earned break, the team returns refreshed and energized for an exciting year ahead. This year brings fresh opportunities, new collaborations, and beginning innovative studies that will deepen our understanding of **acute coronary syndrome, heart failure and pulmonary hypertension**.

We're also thrilled to welcome a new **Clinical Research Officer**, Shaunagh Napier whose wealth of experience in clinical trials will undoubtedly strengthen our efforts.

With innovation, teamwork, and dedication, 2025 is set to be a year of progress and impact. Keep an eye out for recruitment updates or reach out to learn how you can be involved. To a year of meaningful change and lasting impact - wishing everyone a successful and fulfilling year ahead.

REFERRAL OR CONSULTATION

To discuss your patient with an ISLHD Trials Clinician, please phone Illawarra Heart Health Centre on 02 4253 4908 or Email: ISLHD-cardiacresearch@health.nsw.gov.au

ISLHD Cardiovascular Clinical Trials **CURRENTLY OPEN FOR RECRUITMENT**

Scan the QR Code for more information including eligibility criteria

Medication trials

Heart Failure & Inflammation	ATHENA: Ziltivekimab (anti-inflammatory monoclonal anti- body) versus placebo in patients with heart failure, mildly re- duced ejection fraction HFmrEF, or preserved ejection frac- tion HFpEF. Evaluating functional capacity, heart failure symp- toms and systemic inflammation. 4 x Monthly injection	A/Prof Lee	
Acute Myocardial Infarct	ARTEMIS: Ziltivekimab (anti-inflammatory monoclonal anti- body) versus placebo on patients with acute myocardial infarct CV outcome study. Monthly injections	A/Prof Lee	
Acute Coronary Syndrome	LIBREXIA: Milvexian (Factor Xia inhibitor) versus placebo in patients after a recent acute coronary syndrome. Investigating the efficacy and safety. Oral tablet taken twice a day.	A/Prof Lee	1.94.05 E

Intervention trials

Aortic stenosis	EASY-AS: A trial of early valve replacement in severe asymptomatic aortic stenosis	Dr Danson	
Hyperlipidaemia	GOAL ASIA: Guideline Oriented Approach to Lipid Lowering In Asia-Pacific	A/Prof Lee	
LV thrombus	RELEVENT: Resolution of left ventricular thrombus with different anti coagulation strategies	Dr Moragues	
Implant device	PROTECT ICD: Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias following Acute Myocardial In- farction	A/Prof Lee	
Pacemakers	PARTICIPATE: Partnering remote monitoring of implanted cardiac devices with intelligent patient engagement	A/Prof Lee	

Observational trials

Heart Failure	POSEIDON: Observational study looking at prevalence of sys-	A/Prof Lee	影
&	temic inflammation in patients with Atherosclerotic Cardio-		1999
Cardiovascular	vascular disease and Heart Failure		
Disease			

For further information regarding these trials at the Illawarra Heart Health Centre contact: Stephen Mackay (Trial Lead) 02 4253 4624; Martin Walker (Trial Coordinator) 02 4253 4650 email <u>ISLHD-cardiacresearch@health.nsw.gov.au</u>

















